Resolution-Associated Molecular Patterns (RAMPs) as Endogenous Regulators of Glia Functions in Neuroinflammatory Disease.
This article summarizes the available evidence implicating the following RAMPs in CNS physiological processes and neurodegenerative diseases: cardiolipin (CL), prothymosin α (ProTα), binding immunoglobulin protein (BiP), heat shock protein (HSP) 10, HSP 27, and αB-crystallin. Studies on the molecular mechanisms engaged by RAMPs could identify novel glial targets for development of therapeutic agents that effectively slow down neuroinflammatory disorders including AD. PMID: 32614758 [PubMed - as supplied by publisher] (Source: CNS and Neurological Disorders Drug Targets)
Source: CNS and Neurological Disorders Drug Targets - July 2, 2020 Category: Drugs & Pharmacology Authors: Wenzel TJ, Kwong E, Bajwa E, Klegeris A Tags: CNS Neurol Disord Drug Targets Source Type: research

Tumor Treating Fields - behind and beyond inhibiting the cancer cell cycle.
Abstract The unmet need for a safe treatment that significantly improves the overall survival as well as the quality of life of patients with brain tumors has urged researchers to work out new treatment modalities. About 15 years ago it was shown that alternating electric fields significantly impair the growth of cancer cells. Recently, this potentially revolutionary approach called Tumor Treating Fields (TTFs) has been FDA-approved for treatment of glioblastoma as well as mesothelioma. However, despite the promising reports on the potential of TTFs the precise knowledge of the mechanisms of action is still lackin...
Source: CNS and Neurological Disorders Drug Targets - July 2, 2020 Category: Drugs & Pharmacology Authors: Kissling C, Di Santo S Tags: CNS Neurol Disord Drug Targets Source Type: research

Inflammation and Mitochondrial Dysfunction in Autism Spectrum Disorder.
Abstract Autism Spectrum Disorders (ASD) is a severe childhood psychiatric condition with an array of cognitive, language and social impairments that can significantly impact on family life. ASD is classically characterized by reduced communication skills and social interactions, with limitations imposed by repetitive patterns of behavior, interests, and activities. The pathophysiology of ASD is thought to arise from complex interactions between environmental and genetic factors within the context of individual development. A growing body of research has raised the possibility of identifying the aetiological cause...
Source: CNS and Neurological Disorders Drug Targets - June 27, 2020 Category: Drugs & Pharmacology Authors: Gevezova M, Sarafian V, Anderson G, Maes M Tags: CNS Neurol Disord Drug Targets Source Type: research

Transdermal drug delivery systems and their potential on Alzheimer's disease management.
CONCLUSION: In summary, the transdermal administration of Alzheimer's drugs is an interesting and promising topic, which should be further elaborated. PMID: 32552655 [PubMed - as supplied by publisher] (Source: CNS and Neurological Disorders Drug Targets)
Source: CNS and Neurological Disorders Drug Targets - June 18, 2020 Category: Drugs & Pharmacology Authors: Siafaka PI, Bülbül EÖ, Mutlu G, EvrenOkur M, Karantas ID, Okur NÜ Tags: CNS Neurol Disord Drug Targets Source Type: research

Metabolic Adjustments by LncRNAs in Peripheral Neutrophils Partly Account for the Complete Compensation of Asymptomatic MMD Patients.
Abstract BACKGROUNDS: Due to recent development of non-invasive examinations, more asymptomatic patients with moyamoya disease (MMD) have been diagnosed than ever. However, its underlying molecular mechanisms and clinical intervention guidelines are all still obscure. METHODS: Microarray was used to explore those differentially expressed mRNAs and lncRNAs in peripheral neutrophils of asymptomatic MMD patients. Then enrichment analyses based on Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) for those differentially expressed mRNAs and lncRNA associated mRNAs were performed for underlying...
Source: CNS and Neurological Disorders Drug Targets - June 18, 2020 Category: Drugs & Pharmacology Authors: Han Z, Li L, Liu P, Huang Y, Zhang S, Li G, Li F, Zhao H, Tao Z, Wang R, Ma Q, Luo Y Tags: CNS Neurol Disord Drug Targets Source Type: research

The locus of action of CGRPergic monoclonal antibodies against migraine: peripheral over central mechanisms.
l E, Villalón CM Abstract Migraine is a complex neurovascular disorder characterized by attacks of moderate to severe unilateral headache, accompanied by photophobia or other neurological signs. Although an arsenal of antimigraine agents is currently available in the market, not all patients respond to them. As calcitonin gene-related peptide (CGRP) plays a key role in the pathophysiology of migraine, CGRP receptor antagonists (gepants) have been developed. Unfortunately, further pharmaceutical development (for olcegepant and telcagepant) was interrupted due to pharmacokinetic issues observed during the ran...
Source: CNS and Neurological Disorders Drug Targets - June 18, 2020 Category: Drugs & Pharmacology Authors: González-Hernández A, Marichal-Cancino BA, García-Boll E, Villalón CM Tags: CNS Neurol Disord Drug Targets Source Type: research

MAPK: a key player in the development and progression of Stroke.
CONCLUSION: We further elucidated that MAPK signaling pathway molecules can be used as therapeutic targets for stroke, thus promoting the prevention and treatment of stroke. PMID: 32533818 [PubMed - as supplied by publisher] (Source: CNS and Neurological Disorders Drug Targets)
Source: CNS and Neurological Disorders Drug Targets - June 13, 2020 Category: Drugs & Pharmacology Authors: Zheng Y, Han Z, Zhao H, Luo Y Tags: CNS Neurol Disord Drug Targets Source Type: research

Lisdexamfetamine alters BOLD-fMRI activations induced by odor cues in impulsive children.
CONCLUSIONS: We demonstrated that LDX, first, altered the inhibitory pathways of the brain, second, increased activity in large amounts of brain regions which were not activated by smell in drug-naïve patients, third, facilitated a complementary behavioral regulation mechanism, run by the cerebellum, which regulated decision-making and impulsivity in motor and frontal structures. PMID: 32533819 [PubMed - as supplied by publisher] (Source: CNS and Neurological Disorders Drug Targets)
Source: CNS and Neurological Disorders Drug Targets - June 13, 2020 Category: Drugs & Pharmacology Authors: Tobón SSH, Suárez PD, Pérez EB, López JMH, García J, de Celis Alonso B Tags: CNS Neurol Disord Drug Targets Source Type: research

When Sick Brain and Hopelessness Meet: Some Matters on Suicidality in the Neurological Patient.
Abstract Neurological diseases expose individuals to a higher risk of suicidal ideation and suicidal behavior, including completed suicides and suicide attempts. They also represent a paradigmatic arena to study the etio-pathogenic mechanisms underlying suicidality because they are emblematic of the heterogeneity and complexity of mutual interrelationships characterizing this issue. On the one hand, neurological diseases imply strictly biological impairments that are postulated to be the basis of vulnerability to suicide or result in the need for treatments for which a suicidal risk has been hypothesized. On the o...
Source: CNS and Neurological Disorders Drug Targets - June 11, 2020 Category: Drugs & Pharmacology Authors: Costanza A, Amerio A, Aguglia A, Escelsior A, Serafini G, Berardelli I, Pompili M, Amore M Tags: CNS Neurol Disord Drug Targets Source Type: research

Topiramate Decelerates Bicarbonate-Driven Acid-Elimination of Human Neocortical Neurons: Strategic Significance for its Antiepileptic, antimigraine and Neuroprotective Properties.
Abstract BACKGROUND: Mammalian central neurons regulate their intracellular pH (pHi) strongly and even slight pHi-fluctuations can influence inter-/intracellular signaling, synaptic plasticity and excitability. OBJECTIVE: For the first time, we investigated topiramate´s (TPM) influence on pHi- behavior of human central neurons representing a promising target for anticonvulsants and antimigraine drugs. METHODS: In slice-preparations of tissue resected from the middle temporal gyrus of five adults with intractable temporal lobe epilepsy, BCECF-AM-loaded neocortical pyramidal-cells were investigated f...
Source: CNS and Neurological Disorders Drug Targets - June 4, 2020 Category: Drugs & Pharmacology Authors: Bonnet U, Wiemann M Tags: CNS Neurol Disord Drug Targets Source Type: research

Yishen Huazhuo Decoction induces autophagy to promote the clearance of A β1-42 in SAMP8 mice: mechanism research of a traditional Chinese formula against Alzheimer's disease.
Yishen Huazhuo Decoction induces autophagy to promote the clearance of Aβ1-42 in SAMP8 mice: mechanism research of a traditional Chinese formula against Alzheimer's disease. CNS Neurol Disord Drug Targets. 2020 Jun 04;: Authors: Wang K, Sun W, Xu J, Qin Q, Yu Z, Cheng R, Zhang L, Liu S, Zhou Z, Zhang Y, Cui Y Abstract BACKGROUND: Studies have found that autophagy could promote the clearance of Aβ. To promote and maintain the occurrence of autophagy in Alzheimer's disease (AD) might be a potential way to reduce neuronal loss and improve the learning and memory of AD. OBJECTIVE: To invest...
Source: CNS and Neurological Disorders Drug Targets - June 4, 2020 Category: Drugs & Pharmacology Authors: Wang K, Sun W, Xu J, Qin Q, Yu Z, Cheng R, Zhang L, Liu S, Zhou Z, Zhang Y, Cui Y Tags: CNS Neurol Disord Drug Targets Source Type: research

A pivotal role of Nrf2 signaling pathway in spinal cord injury: a prospective therapeutics study.
Abstract The nuclear erythroid 2-related factor 2 (Nrf2) signaling pathway has a main role against oxidative stress and inflammation. Spinal cord injury (SCI) leads to the high secretion of inflammatory cytokines and reactive oxygen species, which disturbs nervous system function and regeneration. Several studies have indicated that the activation of the Nrf2 signaling pathway may be effective against inflammation after SCI. The experimental studies have indicated that many chemical and natural agents act as Nrf2 inducer, which inhibits the SCI progression. Thus, the finding of novel Nrf2-inducer anti-inflammatory...
Source: CNS and Neurological Disorders Drug Targets - June 4, 2020 Category: Drugs & Pharmacology Authors: Farkhondeh T, Pourbagher-Shahri AM, Ashrafizadeh M, Khan H, Forouzanfar F, Aramjoo H, Samarghandian S Tags: CNS Neurol Disord Drug Targets Source Type: research

Evidence On The New Drug Lumateperone (Iti-007) For Psychiatric And Neurological Disorders.
Abstract Lumateperone (ITI-007) is a tosylate salt with binding affinities to receptors implicated in the therapeutic actions of antipsychotic medications, including the serotonin 5HT2A receptors, dopamine D2 and D1 receptors and the serotonin transporter. It has a unique mechanism of action because it simultaneously modulates serotonin, dopamine, and glutamate neurotransmission, implicated in serious mental illness. It can be considered a multi-target-directed ligand and a multifunctional modulator of serotoninergic system with possible precognitive, antipsychotic, antidepressant and anxiolytic properties. Lumate...
Source: CNS and Neurological Disorders Drug Targets - June 1, 2020 Category: Drugs & Pharmacology Authors: Mazza M, Marano G, Traversi G, Sani G, Janiri L Tags: CNS Neurol Disord Drug Targets Source Type: research

In vitro and in vivo neuroprotective effects of Etifoxine in β-amyloidinduced toxicity models.
CONCLUSION: Our results have shown that in these two models, etifoxine could fully prevent neurotoxicity and pathological changes induced by Aβ. These results confirm that TSPO ligands could offer an interesting therapeutic approach in Alzheimer's disease. PMID: 32479250 [PubMed - as supplied by publisher] (Source: CNS and Neurological Disorders Drug Targets)
Source: CNS and Neurological Disorders Drug Targets - June 1, 2020 Category: Drugs & Pharmacology Authors: Riban V, Meunier J, Buttigieg D, Villard V, Verleye M Tags: CNS Neurol Disord Drug Targets Source Type: research

The β-secretase enzyme BACE1: A biochemical enigma for Alzheimer's disease.
The β-secretase enzyme BACE1: A biochemical enigma for Alzheimer's disease. CNS Neurol Disord Drug Targets. 2020 May 26;: Authors: Shah H, Patel A, Parikh V, Nagani A, Bhimani B, Shah U, Bambharoliya T Abstract Beta site amyloid precursor protein cleaving enzyme 1 (BACE1) is a rational target in Alzheimer's disease (AD) drug development due to its role in amyloidogenic cleavage of Amyloid precursor protein (APP) in generating Amyloid β (Aβ). This β-secretase cleaves not only Amyloid precursor protein (APP) and its homologues but also small series of substrate including neuregulin a...
Source: CNS and Neurological Disorders Drug Targets - May 26, 2020 Category: Drugs & Pharmacology Authors: Shah H, Patel A, Parikh V, Nagani A, Bhimani B, Shah U, Bambharoliya T Tags: CNS Neurol Disord Drug Targets Source Type: research

Overview of therapeutic drugs and methods for the treatment of Parkinson's disease.
Abstract Parkinson's disease (PD) is a neurodegenerative disease involving degeneration of dopaminergic neurons of the nigrostrial pathways. Over the past decades, most of the medications for the treatment of PD patients have been used to modulate dopamine concentrations in the basal ganglia. This includes levodopa and its inhibitory metabolizing enzymes. In addition to modulating dopamine concentrations in the brain, there are D2-like dopamine receptor agonists that mimic the action of dopamine to compensate for the deficit in dopamine found in PD patients. Muscarinic antagonists' drugs are used rarely due to som...
Source: CNS and Neurological Disorders Drug Targets - May 24, 2020 Category: Drugs & Pharmacology Authors: Schneider A, Sari AT, Alhaddad H, Sari Y Tags: CNS Neurol Disord Drug Targets Source Type: research

The Combination Of Rtms And Pharmacotherapy On In Vitro Models: A Mini Review.
CONCLUSION: The limited amount of knowledge denotes the need for additional in vitro studies on the combination of rTMS and pharmacotherapy, which could be extended to in vivo studies and ultimately inform the design of clinical trials so as to improve the therapeutic management of patients with a wide array of neuropsychiatric disorders. PMID: 32418533 [PubMed - as supplied by publisher] (Source: CNS and Neurological Disorders Drug Targets)
Source: CNS and Neurological Disorders Drug Targets - May 17, 2020 Category: Drugs & Pharmacology Authors: Pourzitaki C, Dardalas I, Poutoglidou F, Kouvelas D, Kimiskidis VK Tags: CNS Neurol Disord Drug Targets Source Type: research

Interlink between insulin resistance and neurodegeneration with an update on current therapeutic approaches.
CONCLUSION: Research has shown that insulin insensitivity in T2DM leads to neurodegeneration through mechanisms involving a variety of extracellular, membrane receptor, and intracellular signaling pathway disruptions. Some therapeutics, such as intranasal administration of insulin and neuroactive substances have shown promise but face problems related to genetic background, accessibility to the brain, and invasiveness of the procedures. PMID: 32418534 [PubMed - as supplied by publisher] (Source: CNS and Neurological Disorders Drug Targets)
Source: CNS and Neurological Disorders Drug Targets - May 17, 2020 Category: Drugs & Pharmacology Authors: Bhattamisra SK, Shin LY, Saad HIBM, Rao V, Candasamy M, Pandey M, Choudhury H Tags: CNS Neurol Disord Drug Targets Source Type: research

Targeting the PI3K/AKT/mTOR Signaling Pathway in Primary Central Nervous System Lymphoma: Current Status and Future Prospects.
Abstract Primary central nervous system lymphoma (PCNSL) is a rare invasive extranodal non-Hodgkin lymphoma, the vast majority of which is diffuse large B-cell lymphoma (DLBCL). Although high-dose methotrexate-based immunochemotherapy achieves a high remission rate, the risk of relapse and related death remains a crucial obstruction to long-term survival. Novel agents for the treatment of lymphatic malignancies have greatly broadened the horizons of therapeutic options for PCNSL. The PI3K/AKT/mTOR signaling pathway is one of the most important pathways for B-cell malignancy growth and survival. Novel therapies tha...
Source: CNS and Neurological Disorders Drug Targets - May 17, 2020 Category: Drugs & Pharmacology Authors: Xiaowei Z, Yuanbo L Tags: CNS Neurol Disord Drug Targets Source Type: research

Current and Future of Alzheimer's therapy with the best approach.
CONCLUSION: In conclusion, the new approaches seem to aim at examining the prospective neuroprotective activity of diseasemodifying drugs in the pre-symptomatic phases of AD, using biomarkers that detect progression of the disease before the growth of overt dementia. PMID: 32351189 [PubMed - as supplied by publisher] (Source: CNS and Neurological Disorders Drug Targets)
Source: CNS and Neurological Disorders Drug Targets - April 29, 2020 Category: Drugs & Pharmacology Authors: Singh H, Chawla V, Bala R, Dureja H Tags: CNS Neurol Disord Drug Targets Source Type: research

Early Expression of Neuronal Dopaminergic Markers in a Parkinson's Disease Model in Rats Implanted with Enteric Stem Cells (ENSCs).
CONCLUSION: Our novel results suggest that ENSCs possess differentiating, proliferative and restorative potential that may offer therapeutic modalities to attenuate neurodegenerative events with inherent demise of DAergic neurons. PMID: 32303175 [PubMed - as supplied by publisher] (Source: CNS and Neurological Disorders Drug Targets)
Source: CNS and Neurological Disorders Drug Targets - April 17, 2020 Category: Drugs & Pharmacology Authors: Parra-Cid C, Orozco-Castillo E, García-López J, Contreras-Figueroa E, Ramos-Languren LE, Ibarra C, Carreón-Rodríguez A, Aschner M, Königsberg M, Santamaría A Tags: CNS Neurol Disord Drug Targets Source Type: research

CSF levels of the endocannabinoid anandamide are reduced in patients with untreated narcolepsy type 1: a pilot study.
Conclusion We hypothesize that the endocannabinoid system is dysregulated in NT1. PMID: 32148204 [PubMed - as supplied by publisher] (Source: CNS and Neurological Disorders Drug Targets)
Source: CNS and Neurological Disorders Drug Targets - March 9, 2020 Category: Drugs & Pharmacology Authors: Romigi A, Bari M, Liguori C, Izzi F, Rapino C, Nuccetelli M, Battista N, Bernardini S, Centonze D, Mercuri N, Placidi F, Maccarrone M Tags: CNS Neurol Disord Drug Targets Source Type: research

Oxidative stress in the pathogenesis of Alzheimer's disease and cerebrovascular disease with therapeutic implications.
Abstract The significant gain in life expectancy led to an increase in the incidence and prevalence of dementia. Although vascular risk factors have long and repeatedly been shown to increase the risk of Alzheimer's disease (AD), translating these findings into effective preventive measures has failed. In addition, the finding that incident ischemic stroke approximately doubles the risk of a patient to develop AD has been recently reinforced. Current knowledge and pathogenetic hypotheses of AD are discussed. The implication of oxidative stress in the development of AD is reviewed, with special emphasis on its sudd...
Source: CNS and Neurological Disorders Drug Targets - March 3, 2020 Category: Drugs & Pharmacology Authors: Jurcau A, Simion A Tags: CNS Neurol Disord Drug Targets Source Type: research

Risk analysis of lurasidone in patients with schizophrenia and bipolar depression.
CONCLUSION: In conclusion, Marketing Authorization Holder (MAH) and Regulatory Authorities (RA) should monitor these adverse drug reactions. PMID: 32124704 [PubMed - as supplied by publisher] (Source: CNS and Neurological Disorders Drug Targets)
Source: CNS and Neurological Disorders Drug Targets - March 3, 2020 Category: Drugs & Pharmacology Authors: Modugula H, Kumar A Tags: CNS Neurol Disord Drug Targets Source Type: research

Scopolamine, a toxin-induced experimental model used for research in Alzheimer's disease.
Abstract Scopolamine as a drug is often used to treat motion sickness. Derivatives of scopolamine have also found applications as antispasmodic drug among others. In neuroscience-related research, it is often used to induce cognitive disorders in experimental models as it is readily permeates the blood brain barrier. In the context of Alzheimer's disease, its effects include causing cholinergic dysfunction and increasing amyloid-β deposition, both of which are hallmarks of the disease. Hence, the application of scopolamine in Alzheimer's disease research is proven pivotal but seldom discussed. In this review,...
Source: CNS and Neurological Disorders Drug Targets - February 13, 2020 Category: Drugs & Pharmacology Authors: Chen WN, Yeong KY Tags: CNS Neurol Disord Drug Targets Source Type: research

Sialuria-Related Intellectual Disability in Children and Adolescent of Pakistan: Tenth Patient Described has a Novel Mutation in GNE gene.
Abstract Sialuria is a rare inborn error of metabolism caused by excessive synthesis of sialic acid due to the mutation in the binding site of the cytidine monophosphate-sialic acid of UDP-GlcNAc 2-epimerase/ManNAc kinase (GNE/MNK). This is the first study investigating the molecular basis of neuronal disorders exhibiting sialuria in Pakistani children/ adolescents. Current study genotyped GNE SNPs rs121908621, rs121908622 and rs121908623 by using PCR, RFLP, and DNA sequencing methods. Socioeconomic and clinical histories were also recorded. Our data suggest that clinical symptoms and financial status play a signi...
Source: CNS and Neurological Disorders Drug Targets - February 12, 2020 Category: Drugs & Pharmacology Authors: Ishtiaq H, Siddiqui S, Nawaz R, Jamali KS, Khan AG Tags: CNS Neurol Disord Drug Targets Source Type: research

Neuronal Excitability in Epileptogenic Zones Regulated by the Wnt/ Β-Catenin Pathway.
Neuronal Excitability in Epileptogenic Zones Regulated by the Wnt/Β-Catenin Pathway. CNS Neurol Disord Drug Targets. 2020 Jan 20;: Authors: Rubio C, Taddei E, Acosta J, Custodio V, Paz C Abstract Epilepsy is a neurological disorder that involves abnormal and recurrent neuronal discharges, producing epileptic seizures. Recently, it has been proposed that the Wnt signaling pathway is essential for central nervous system development and function because it modulates important processes such as hippocampal neurogenesis, synaptic clefting, and mitochondrial regulation. Wnt/β-catenin signaling reg...
Source: CNS and Neurological Disorders Drug Targets - January 20, 2020 Category: Drugs & Pharmacology Authors: Rubio C, Taddei E, Acosta J, Custodio V, Paz C Tags: CNS Neurol Disord Drug Targets Source Type: research

Stingless bee honey reduces anxiety and improves memory of the metabolic disease-induced rats.
CONCLUSION: KH has the ability to normalise blood glucose and reduce serum triglyceride and LDL levels in MetS rats, while behavior studies complement its effect on anxiety and memory. This shows a promising role of KH in attenuating neurodegenerative diseases through the antioxidant activity of its polyphenolic content. PMID: 31957619 [PubMed - as supplied by publisher] (Source: CNS and Neurological Disorders Drug Targets)
Source: CNS and Neurological Disorders Drug Targets - January 16, 2020 Category: Drugs & Pharmacology Authors: Arshad N', Lin TS, Yahaya MF Tags: CNS Neurol Disord Drug Targets Source Type: research

BDNF-TrkB and proBDNF-p75NTR/sortilin signaling pathways are involved in mitochondria-mediated neuronal apoptosis in dorsal root ganglia after sciatic nerve transection.
CONCLUSION: proBDNF induced apoptosis in SGCs and sensory neurons in DRG following SNT. The proBDNF signaling pathway is a potential novel therapeutic target for reducing sensory neuron and SGC loss following peripheral nerve injury. PMID: 31957620 [PubMed - as supplied by publisher] (Source: CNS and Neurological Disorders Drug Targets)
Source: CNS and Neurological Disorders Drug Targets - January 16, 2020 Category: Drugs & Pharmacology Authors: Wang X, Ma W, Wang T, Yang J, Wu Z, Liu K, Dai Y, Zang C, Liu W, Liu J, Liang Y, Guo J, Li L Tags: CNS Neurol Disord Drug Targets Source Type: research

The role of Annexin A1 and formyl peptide receptor 2/3 signaling on chronic corticosterone-induced depression-like behaviors and impairment in hippocampal-dependent memory.
CONCLUSION: In conclusion, the absence of the ANXA1 protein, even more than the absence of its main receptor (FPR 2/3), was fundamental to the inhibitory action of GC on the HPA axis; it also maintained the hippocampal homeostasis by preventing neuronal damage associated with depression. PMID: 31914916 [PubMed - as supplied by publisher] (Source: CNS and Neurological Disorders Drug Targets)
Source: CNS and Neurological Disorders Drug Targets - January 6, 2020 Category: Drugs & Pharmacology Authors: Peritore AF, Crupi R, Scuto M, Gugliandolo E, Siracusa R, Impellizzeri D, Cordaro M, D'amico R, Fusco R, Di Paola R, Cuzzocrea S Tags: CNS Neurol Disord Drug Targets Source Type: research

Plasma indoleamine-2,3-dioxygenase (IDO) is increased in drug-na ïve major depressed patients and treatment with sertraline and ketoprofen normalizes IDO in association with pro-inflammatory and immune-regulatory cytokines.
CONCLUSION: MDD is accompanied by activated immune-inflammatory pathways (including IDO) and the compensatory immune-regulatory system (CIRS). The clinical efficacy of antidepressant treatment may be ascribed at least in part to decrements in IDO and the immune-inflammatory response. These treatments also significantly reduce the more beneficial properties of T helper-2 and T regulatory (Treg) subsets. Future research should develop immune treatments that target the immune-inflammatory response in MDD while enhancing the CIRS. PMID: 31894751 [PubMed - as supplied by publisher] (Source: CNS and Neurological Disorders Drug Targets)
Source: CNS and Neurological Disorders Drug Targets - January 1, 2020 Category: Drugs & Pharmacology Authors: Al-Hakeim HK, Twayej AJ, Al-Dujaili AH, Maes M Tags: CNS Neurol Disord Drug Targets Source Type: research

Pharmacokinetics and Acute Toxicity of a Histone Deacetylase Inhibitor, Scriptaid, and Its Neuroprotective Effects in Mice After Intracranial Hemorrhage.
CONCLUSION: These findings indicate that Scriptaid is safe and can alleviate brain injury after ICH, thereby providing a foundation for the pharmacological action of Scriptaid in the treatment of brain injury after ICH. PMID: 31858907 [PubMed - as supplied by publisher] (Source: CNS and Neurological Disorders Drug Targets)
Source: CNS and Neurological Disorders Drug Targets - December 19, 2019 Category: Drugs & Pharmacology Authors: Yang H, Gao X, Su J, Jiang H, Lei Y, Ni W, Gu Y Tags: CNS Neurol Disord Drug Targets Source Type: research

Synthesis and evaluatation of N-substituted (Z)-5-(benzo[d][1,3]dioxol-5-ylmethylene)-2-thioxothiazolidin-4-one derivatives and 5-substituted-thioxothiazolidindione derivatives as potent anticonvulsant agents.
CONCLUSION: Stiripentol is a good lead compound for further structural modification. We have got the compound 4e, which display remarkable anticonvulsant activities, and the NaV1.1 channel inhibition was involved in the action mechanism of 4e. PMID: 31742497 [PubMed - as supplied by publisher] (Source: CNS and Neurological Disorders Drug Targets)
Source: CNS and Neurological Disorders Drug Targets - November 19, 2019 Category: Drugs & Pharmacology Authors: Dong S, Liu Y, Xu J, Hu Y, Huang L, Wang Z Tags: CNS Neurol Disord Drug Targets Source Type: research

Structurally Related Edaravone Analogues: Synthesis, Antiradical, Antioxidant, and Copper-Chelating Properties.
CONCLUSION: Overall, this study reveals a subset of edaravone analogues with interesting properties. Further investigation of these compounds is foreseen in relevant models of oxidative stress-associated diseases in order to assess their therapeutic potential in such conditions. PMID: 31724516 [PubMed - as supplied by publisher] (Source: CNS and Neurological Disorders Drug Targets)
Source: CNS and Neurological Disorders Drug Targets - November 13, 2019 Category: Drugs & Pharmacology Authors: LeBlanc A, Cuperlovic-Culf M, Morin PJ, Touaibia M Tags: CNS Neurol Disord Drug Targets Source Type: research

Pharmacotherapy of Down's syndrome: When and Which?
Abstract Down syndrome (DS) is an important genetic disease that besides cerebral functions involves many other body systems. The postnatal approach to treat this genetic disease includes intervention on various related diseases (e.g. heart failure, respiratory, oral, ear and hearing disorders). Different treatments proposed barely improve the quality of life of these subjects. Another approach to the treatment of DS considering the possibility to intervene on the embryo was recently proposed. This paper has reviewed different aspects of DS and has analyzed the results of DS treatment in an animal model, namely th...
Source: CNS and Neurological Disorders Drug Targets - November 13, 2019 Category: Drugs & Pharmacology Authors: Tayebati SK, Cecchi A, Martinelli I, Carboni E, Amenta F Tags: CNS Neurol Disord Drug Targets Source Type: research

A Review for Lithium: Pharmacokinetics, Drug Design and Toxicity.
CONCLUSION: Various formulations of lithium have potential for treating neurodegenerative brain diseases but further study on their pharmacokinetics will be required in order to determine the optimal formulation, dosage and route of administration. PMID: 31724518 [PubMed - as supplied by publisher] (Source: CNS and Neurological Disorders Drug Targets)
Source: CNS and Neurological Disorders Drug Targets - November 13, 2019 Category: Drugs & Pharmacology Authors: Jinhua W, Sawmiller D, Wheeldon B, Jun T Tags: CNS Neurol Disord Drug Targets Source Type: research

Omega-3 Fatty Acids as Druggable Therapeutics for Neurodegenerative Disorders.
Abstract Neurodegenerative disorders are commonly associated with a complex pattern of pathophysiological hallmarks including increased oxidative stress and neuroinflammation, which makes their treatment challenging. Omega-3 fatty acids (O3FA) are natural products with reported neuroprotective, anti-inflammatory, and antioxidant effects. These effects have been attributed to their incorporation into neuronal membranes or via activation of intracellular or recently discovered cell-surface receptors (i.e., free-fatty acid receptors; FFAR). Molecular docking studies have investigated the roles of O3FA as FFAR agonist...
Source: CNS and Neurological Disorders Drug Targets - November 13, 2019 Category: Drugs & Pharmacology Authors: Chitre NM, Moniri NH, Murnane KS Tags: CNS Neurol Disord Drug Targets Source Type: research

Neurological disorders associated to long term tramadol utilization: Pathological mechanisms and future perspective.
Abstract Tramadol is a synthetic analog of codeine used to treat pain of moderate to severe intensity and is reported to have neurotoxic potential. At therapeutic dose, tramadol does not cause major side effects in comparison to other opioid analgesics, and is useful for the management of neurological problems like anxiety and depression. Long term utilization of tramadol is associated with various neurological disorders like seizures, serotonin syndrome, Alzheimer's disease and Parkinson's disease. Tramadol produces seizures through inhibition of nitric oxide, serotonin reuptake and inhibitory effects on GABA rec...
Source: CNS and Neurological Disorders Drug Targets - November 12, 2019 Category: Drugs & Pharmacology Authors: Raj K, Chawla P, Singh S Tags: CNS Neurol Disord Drug Targets Source Type: research

Madecassic acid reduces fast transient potassium channels and promotes neurite elongation in hippocampal CA1 neurons.
CONCLUSIONS & IMPLICATIONS: The data demonstrated that MA increased neurite outgrowth by internalizing AKv channels in neurons. Any alterations in the precise density of ion channels can lead to the deleterious consequences on health because it changes the electrical and mechanical function of a neuron or a cell. Modulating ion channel's density is an exciting research in order to develop novel drugs for the therapeutic treatment of various diseases of CNS. PMID: 31713492 [PubMed - as supplied by publisher] (Source: CNS and Neurological Disorders Drug Targets)
Source: CNS and Neurological Disorders Drug Targets - November 10, 2019 Category: Drugs & Pharmacology Authors: Siddiqui S, Khan F, Jamali KS, Musharraf SG Tags: CNS Neurol Disord Drug Targets Source Type: research

Somatostatin type 2 receptor antibody enhances mechanical hyperalgesia in the dorsal root ganglion neurons after sciatic nerve-pinch injury: Evidence of molecular and behavioral studies.
CONCLUSION: The current data suggested that inhibitory changes in proteins from the apoptotic pathway in anti-SSTR2-treated groups might be taking place to overcome the protein deficits caused by SSTR2 antibody and supported the new therapeutic intervention with SSTR2 antagonist for neuronal degeneration following nerve injury. PMID: 31686636 [PubMed - as supplied by publisher] (Source: CNS and Neurological Disorders Drug Targets)
Source: CNS and Neurological Disorders Drug Targets - October 31, 2019 Category: Drugs & Pharmacology Authors: Xiang Q, Li JJ, Li CY, Tian RB, Li XH Tags: CNS Neurol Disord Drug Targets Source Type: research

Prion peptide 106-126 degradation potential of Serratiopetidase and Lumbrokinase - an in vitro and in silico perspective.
Abstract PrPC is a host-encoded prion protein which gets post translationally modified into a transmissible, β-sheet rich disease associated protein called PrPSc, responsible for the Prion disease including mad cow disease in cattles and CJD in humans. The PrP 106-126 region in PrPSc peptide initiates the conformational change in that protein leading fibrillation. Any agent that can destabilize or disintegrate such proteins can be served as a potential drug candidate for Prion diseases. In the present study, an enzyme Lumbrokinase (LK) was isolated from earthworm and its activity was exploited towards PrP 106...
Source: CNS and Neurological Disorders Drug Targets - October 21, 2019 Category: Drugs & Pharmacology Authors: Metkar SK, Ghosh S, Girigoswami A, Girigoswami K Tags: CNS Neurol Disord Drug Targets Source Type: research

Cannabidiol partially blocks the sleepiness in hypocretin-deficient rats. Preliminary data.
er-Colín R Abstract Excessive daytime sleepiness and cataplexy are among the symptoms of narcolepsy, a sleep disorder caused by the loss of hypocretin/orexin (HCRT/OX) neurons placed into the hypothalamus (LH). Several treatments for managing narcolepsy include diverse drugs to induce alertness, such as antidepressants, amphetamine, or modafinil, etc. Recent evidence has shown that cannabidiol (CBD), a non-psychotropic derived from Cannabis sativa, shows positive therapeutic effects in neurodegenerative disorders, including Parkinson´s disease. Furthermore, CBD provokes alertness and enhances wake-rel...
Source: CNS and Neurological Disorders Drug Targets - October 21, 2019 Category: Drugs & Pharmacology Authors: Murillo-Rodríguez E, Millán-Aldaco D, Palomero-Rivero M, Morales-Lara D, Mechoulam R, Drucker-Colín R Tags: CNS Neurol Disord Drug Targets Source Type: research

Combined ischemic preconditioning and resveratrol improves blood-brain barrier breakdown via Hippo/YAP/TAZ signaling pathway.
The objective of this study was to survey the treatment function of the activation of the Hippo/YAP signaling pathway by combined ischemic preconditioning (IPC) and resveratrol (RES) before brain ischemia/reperfusion improves blood-brain barrier (BBB) disruption in rats. Sprague-Dawley (SD) rats were pretreated with 20 mg/kg RES and IPC and then subjected to 2 h of ischemia and 22 h of reperfusion. The brain tissues were collected; the cerebral infarct volume was determined; the Evans blue (EB) level, the brain water content (BWC) and apoptosis were assessed; and the expressions of YAP and TAZ were investigated in cerebral...
Source: CNS and Neurological Disorders Drug Targets - October 21, 2019 Category: Drugs & Pharmacology Authors: Hong G, Yan Y, Zhong Y, Chen J, Tong F, Ma Q Tags: CNS Neurol Disord Drug Targets Source Type: research

Gut Microbiome: Lactation, Childbirth, Lung Dysbiosis, Animal Modeling, Stem Cell Treatment, and CNS disorders.
Abstract Here, we summarized recent advances in laboratory and clinical research on gut microbiome. The goal is to highlight recent discoveries on the biology and behavioral manifestations of gut microbiomes under normal and pathologic conditions. With this new scientific knowledge, we wish to cultivate cross-fertilization of science across multi-disciplines in the hopes of exploiting the gut microbiome as a key component of human development and its dysbiosis may signal pathological alterations that can be therapeutically targeted for regenerative medicine. In the end, we identify innovative research avenues that...
Source: CNS and Neurological Disorders Drug Targets - October 21, 2019 Category: Drugs & Pharmacology Authors: Corey S, Kvederis L, Kingsbury C, Bonsack B, R Sanberg P, Castelli V, Lee JY, V Borlongan C Tags: CNS Neurol Disord Drug Targets Source Type: research

The structure and function of α, β and γ-Secretase as therapeutic target enzymes into the development of Alzheimer's disease: A review.
The structure and function of α, β and γ-Secretase as therapeutic target enzymes into the development of Alzheimer's disease: A review. CNS Neurol Disord Drug Targets. 2019 Oct 11;: Authors: Ahmad SS, Khan S, Kamal MA, Wasi U Abstract Alzheimer's disease is a progressive neurodegenerative disorder that affects the central nervous system. There are several factors that cause AD, like, intracellular hyper-phosphorylated Tau tangles, collection of extracellular Amyloid-β42 and generation of reactive oxygen species due to mitochondrial dysfunction. This review analyses the most activ...
Source: CNS and Neurological Disorders Drug Targets - October 11, 2019 Category: Drugs & Pharmacology Authors: Ahmad SS, Khan S, Kamal MA, Wasi U Tags: CNS Neurol Disord Drug Targets Source Type: research

Role of Neuroimaging Modality in the Assessment of Oxidative Stress in Brain: A Comprehensive Review.
CONCLUSION: In the present review article we present an overview of the role of neuroimaging modalities in the diagnosis, and longitudinal assessment during treatment of the OS induced changes. PMID: 31580247 [PubMed - in process] (Source: CNS and Neurological Disorders Drug Targets)
Source: CNS and Neurological Disorders Drug Targets - October 5, 2019 Category: Drugs & Pharmacology Authors: Pareek V, Nath B, Roy PK Tags: CNS Neurol Disord Drug Targets Source Type: research

Neuro-psychiatric alterations in patients with diabetic foot syndrome.
I, Cauli O Abstract Diabetic foot syndrome (DFS) is a common long-term complication of diabetes mellitus. DFS has recently been associated with adverse effects in brain function which could further impair the quality of life of these patients, as well as increase the social and economic burden, morbidity, and premature mortality of the disease. The current knowledge of neuropsychiatric alterations e.g. cognitive impairment, gait disorder, depression, and quality of life in patients with diabetic foot syndrome is summarized. The cognitive domains altered in DFS are executive function, memory, and psychomotor speed...
Source: CNS and Neurological Disorders Drug Targets - October 1, 2019 Category: Drugs & Pharmacology Authors: Navarro-Flores E, Pérez-Ros P, Fm MA, Julían-Rochina I, Cauli O Tags: CNS Neurol Disord Drug Targets Source Type: research

Carvedilol promotes retinal ganglion cell survival following optic nerve injury via ASK1-p38 MAPK pathway.
Abstract Carvedilol, which is considered as a nonselective β-adrenoreceptor blocker, has many pleiotropic activities. It also causes great influence on neuroprotection because of its antioxidant ability. It is shown in this research that carvedilol could cause influence on preventing retinal ganglion cell (RGC) death caused by optic nerve injury (ONI) as an experimental model. RGC death after ONI could be decreased following carvedilol treatment. And in vivo retinal imaging revealed that carvedilol can effectively prevent retinal degeneration. Moreover, it was demonstrated that carvedilol inhibited ONI-induce...
Source: CNS and Neurological Disorders Drug Targets - October 1, 2019 Category: Drugs & Pharmacology Authors: Liu B, Liu YJ Tags: CNS Neurol Disord Drug Targets Source Type: research

Role of flavonoids in neurodegenerative disorders with special emphasis on tangeritin.
Abstract Flavonoids are naturally occurring plant polyphenols found universally in all fruits, vegetables and medicinal plants. They have emerged as a promising candidate in the formulation of treatment strategies for various neurodegenerative disorders. The use of flavonoid rich plant extracts and food in dietary supplementation have shown favourable outcomes. The present review describes the types, properties and metabolism of flavonoids. Neuroprotective role of various flavonoids and the possible mechanism of action in brain against the neurodegeneration have been described in detail with special emphasis on th...
Source: CNS and Neurological Disorders Drug Targets - September 16, 2019 Category: Drugs & Pharmacology Authors: Fatima A, Siddique YH Tags: CNS Neurol Disord Drug Targets Source Type: research

Jingshu Keli and Its Components Notoginsenoside R1and Ginsenoside Rb1 Alleviate the Symptoms of Cervical Myelopathy through Kir3.1 Mediated Mechanisms.
Abstract ervical spondylotic myelopathy (CSM) is one of the most serious spinal cord disorders in adults. Pharmacological modulation of ion channels is a common strategy to interfere with CSM and prevent neuronal damage. Here, we investigated the effects of Jingshu Keli (JSKL), a traditional Chinese herbal formula, on CSM-related gait abnormality, mechanical allodynia and thermal hyperalgesia, and assessed the neuronal mechanisms of JSKL on cultured brainstem cells. Behavioral tests and patch clamp recordings were performed to make this assessment. In our study, we found that JSKL significantly recovered the gait performance (P
Source: CNS and Neurological Disorders Drug Targets - September 11, 2019 Category: Drugs & Pharmacology Authors: Yan R, Chen R, Wang J, Shi J, Xu Z, Liu L, Dos Santos WF Tags: CNS Neurol Disord Drug Targets Source Type: research